Avandia raises heart attack risk: NEJM analysis

Share this article:
GlaxoSmithKline’s Type-2 diabetes treatment Avandia (rosiglitazone) “significantly increases” the risk of heart attacks, according to an analysis of studies published yesterday on the Web site of The New England Journal of Medicine (NEJM). The analysis, conducted by prominent Cleveland Clinic cardiologist Steven Nissen, also found that rosiglitazone increased the risk of death from cardiovascular causes that had “borderline significance.” Overall, the analysis concluded that patients receiving rosiglitazone had a 43% increase in the risk of having a heart attack, compared to patients not receiving the drug--a “significant increase” Nissen said. The analyzed trials involved 15,560 patients who received drugs containing rosiglitazone and 12,283 who either received other drugs or a placebo. GlaxoSmithKline said in a statement it strongly disagreed with the conclusions of the article which it said are based on incomplete evidence and a methodology that the author admits has significant limitations. “GSK stands firmly behind the safety of Avandia when used appropriately, and we believe its significant benefits continue to outweigh any treatment risks,” the drugmaker said. GlaxoSmithKline added that longer term studies of the drug are currently under way. The FDA said in a statement it has not yet confirmed the clinical significance of the reported increased risk in the studies and is not asking GlaxoSmithKline to take any specific action at this time. Avandia was approved in 1999 for treatment of Type 2 diabetes, a disease that affects about 18 to 20 million Americans. Avandia had US sales of approximately $2.2 billion in 2006.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...